“…The MAb biz, which recognizes a complex epitope in the CD4-binding domain of envelope surface unit gp120 (36), neutralized 3 of the 10 variants tested, with IC 50 s of 0.8, 9.6, and 41.7 g/ml ( Table 2). The 2F5 and 4E10, which target the DKW and WFXI motifs, respectively, in the envelope transmembrane unit gp41 (3,32,34,43,49), neutralized nine and seven variants, respectively, with various potencies. Variants with changes within the antibody epitope (e.g., BF535.A1 and BJ412.S3) were resistant to neutralization by that MAb.…”